



Patient Reported Outcomes

Dibattito strutturato. PROs: still a Cinderella outcome? Giovanni L. PAPPAGALLO (coordina tutti i relatori)

L. J. Fallowfield

Quality of life assessment using patientreported outcome (PRO) measures: still a Cinderella outcome?

Sussex Health Outcomes Research & Education in Cancer, Brighton & Sussex Medical School, University of Sussex, Brighton, UK (E-mail: l.j.fallowfield@sussex.ac.uk)

We have to do better in our evaluation of expensive novel products. The sometimes modest OS or more often PFS gains that excite clinical scientists and pharma share-holders may be of little value to patients experiencing some serious and burdensome side-effects. Conclusions stating that 'patients found sideeffects tolerable' should be viewed with some skepticism as trials that are conducted for registration and licensing purposes rarely have lengthy enough follow-up to chart some of the problems that emerge later in the clinic [3].

Parliamone insieme...



... ma facciamo attenzione ai possibili problemi!

Parliamone insieme...



... ma facciamo attenzione ai possibili problemi!



- Blinding is often difficult
- Data are often missing or incomplete
- Clinical significance of small changes unknown
- Few validated instruments



- Blinding is often difficult
- Data are often missing or incomplete
- Clinical significance of small changes unknown
- Few validated instruments

Opel-label design ALSO when masking is feasible...

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

Brian I Rini, Bernard Escudier, Piotr Tomczak, Andrey Kaprin, Cezary Szczylik, Thomas E Hutson, M Dror Michaelson, Vera A Gorbunova, Martin E Gore, Igor G Rusakov, Sylvie Negrier, Yen-Chuan Ou, Daniel Castellano, Ho Yeong Lim, Hirotsugu Uemura, Jamal Tarazi, David Cella, Connie Chen, Brad Rosbrook, Sinil Kim, Robert J Motzer

Lancet 2011; 378: 1931-39

Patients and investigators were not masked to study treatment. Progression-free survival and objective response rate were assessed by a masked independent radiology review. If no patient blinding was performed...



... were they **unbiased** when filling the QoL questionnaire?

Endpoints of benefit and endpoints of harm BOTH contribute to Quality Assessment!




- Blinding is often difficult
- Data are often missing or incomplete
- Clinical significance of small changes unknown
- Few validated instruments

Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma:

PISCES Study

Bernard Escudier, Camillo Porta, Petri Bono, Thomas Powles, Tim Eisen, Cora N. Sternberg, Jürgen E. Gschwend, Ugo De Giorgi, Omi Parikh, Robert Hawkins, Emmanuel Sevin, Sylvie Négrier, Sadya Khan, Jose Diaz, Suman Redhu, Faisal Mehmud, and David Cella J Clin Oncol 32. © 2014 by American Society of Clinical Oncology



Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study Bernard Escudier, Camillo Porta, Petri Bono, Thomas Powles, Tim Eisen, Cora N. Sternberg, Jürgen E. Gschwend, Ugo De Giorgi, Omi Parikh, Robert Hawkins, Emmanuel Sevin, Sylvie Négrier, Sadya Khan, Jose Diaz, Suman Redhu, Faisal Mehmud, and David Cella


J Clin Oncol 32. © 2014 by American Society of Clinical Oncology

Primary end point (n = 114)

Patients who completed full study treatment (n = 80)

All questionnaires (n = 126)

Worst case: imputation of sunitinib preference for study withdrawals (n = 166)



Mean (90% CI) percentage of patients expressing preference for pazopanib
 Mean (90% CI) percentage of patients expressing preference for sunitinib

Increasing Rate of Preference




- Blinding is often difficult
- Data are often missing or incomplete
- Clinical significance of small changes unknown
- Few validated instruments



Recent statement by the American Statistical Association about p-values (Wasserstein & Lazar, Am Stat 2016;70:129-33)

• P-values do not measure the probability that a hypothesis is true.



- Scientific conclusions and policy decisions should not be based only on p <0.05.
- A p-value does not measure the size of an effect or the importance of a result.





Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

Robert J. Motzer, M.D., Thomas E. Hutson, D.O., David Cella, Ph.D., James Reeves, M.D., Robert Hawkins, M.B., B.S., Ph.D., Jun Guo, Ph.D.,
Paul Nathan, M.B., B.S., Ph.D., Michael Staehler, M.D., Paul de Souza, M.B., B.S., Ph.D., Jaime R. Merchan, M.D., Ekaterini Boleti, M.D., Ph.D., Kate Fife, M.D.,
Jie Jin, M.D., Robert Jones, Ph.D., Hirotsugu Uemura, M.D., Ph.D., Ugo De Giorgi, M.D., Ulrika Harmenberg, M.D., Ph.D., Jinwan Wang, M.D., Cora N. Sternberg, M.D., Keith Deen, M.S., Lauren McCann, Ph.D., Michelle D. Hackshaw, Ph.D., Rocco Crescenzo, D.O., Lini N. Pandite, M.D., and Toni K. Choueiri, M.D.
N Engl J Med 2013;369:722-31

Table 2. Change in Health-Related Quality of Life during the First 6 Months for 927 Patients Treated in the Study.*							
Instrument	Pazopanib	Sunitinib	Difference in Mean Change from Baseline Score with Pazopanib vs. Sunitinib;	P Value ∫	Drug Favored According to Significant Difference¶	Effect Size	
	number of patients						
FACIT-F**	377	403	2.32 구	< 0.001	Pazopanib	0.24	
FKSI-19**							
Treatment side effects	351	382	0.31	0.03	Pazopanib	0.14	
Disease-related physical symptoms	378	407	0.78	0.03	Pazopanib	0.13	
Disease-related emotional symptoms	370	402	-0.05	0.41	Neither	-0.04	
Functional well-being	378	403	0.31	0.10	Neither	0.09	
Total score	377	408	1.41	0.02	Pazopanib	0.14	

Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

Robert J. Motzer, M.D., Thomas E. Hutson, D.O., David Cella, Ph.D., James Reeves, M.D., Robert Hawkins, M.B., B.S., Ph.D., Jun Guo, Ph.D.,
Paul Nathan, M.B., B.S., Ph.D., Michael Staehler, M.D., Paul de Souza, M.B., B.S., Ph.D., Jaime R. Merchan, M.D., Ekaterini Boleti, M.D., Ph.D., Kate Fife, M.D.,
Jie Jin, M.D., Robert Jones, Ph.D., Hirotsugu Uemura, M.D., Ph.D., Ugo De Giorgi, M.D., Ulrika Harmenberg, M.D., Ph.D., Jinwan Wang, M.D., Cora N. Sternberg, M.D., Keith Deen, M.S., Lauren McCann, Ph.D., Michelle D. Hackshaw, Ph.D., Rocco Crescenzo, D.O., Lini N. Pandite, M.D., and Toni K. Choueiri, M.D.
N Engl J Med 2013;369:722-31

Table 2. Change in Health-Related Quality of Life during the First 6 Months for 927 Patients Treated in the Study.*							
Instrument	Pazopanit	o Sunitinib	Difference in Mean Change from Baseline Sco with Pazopanib vs. Sunitinib;	re P Value§	Drug Favored According to Significant Difference¶	Effect Size	
number of patients							
FACIT-F**	377	403	2.32	<0.001	Pazopanib	0.24	
FKSI-19**							
Treatment side effects	3			0.03	Pazopanib	0.14	
Disease-related physical symptoms	3	Rilevanza c da rappoi		0.03	Pazopanib	0.13	
Disease-related emotional symptoms	3	M.I.D. specifica		0.41	Neither	-0.04	
Functional well-being	378	403	0.31	0.10	Neither	0.09	
Total score	377	408	1.41	0.02	Pazopanib	0.14	

The <u>Functional Assessment of Chronic Illness Therapy</u> (FACIT) Measurement System: properties, applications, and interpretation Kimberly Webster, David Cella^{*} and Kathleen Yost

Health and Quality of Life Outcomes 2003, 1:79

Instrument Scale/Subscale		Scale/Subscale MID (points)	
FACT-G	PWB	2–3	[28]
	SWB	NA	
	EWB	2*	[28,29]
	FWB	2–3	[28]
	Total FACT-G	3–7	[27,28,30,31]
ACT-Anemia	Fatigue Subscale	3–4	[27,31]
	TOI-Fatigue	5	[27]
	TOI-Anemia	6	
	Total FACT-Anemia	7	
ACT-Breast	Breast cancer subscale	2–3	[30]
	TOI-Breast	5–6	
	Total FACT-Breast	7–8	
ACT-Colorectal	Colorectal cancer subscale	2–3	[32]
	TOI-Colorectal	4–6	
	Total FACT-Colorectal	5–8	
FACT-Head & Neck	Total FACT-Head & Neck	6-12	[33]
ACT-Lung	Lung cancer subscale	2–3	[34]
	TOI-Lung	5–6	

Table 1: Minimally important differences for select FACIT scales

*This MID should be considered tentative as it may be revised based on future research.



- Blinding is often difficult
- Data are often missing or incomplete
- Clinical significance of small changes unknown
- Few validated instruments

Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Amylou C. Dueck, PhD; Tito R. Mendoza, PhD; Sandra A. Mitchell, PhD, CRNP, AOCN; Bryce B. Reeve, PhD; Kathleen M. Castro, RN, MS, AOCN; Lauren J. Rogak, MA; Thomas M. Atkinson, PhD; Antonia V. Bennett, PhD; Andrea M. Denicoff, MS, RN, ANP; Ann M. O'Mara, PhD, RN, FAAN; Yuelin Li, PhD; Steven B. Clauser, PhD, MPA; Donna M. Bryant, MSN, ANP; BC, OCN, CCRC; James D. Bearden III, MD, FACP; Theresa A. Gillis, MD; Jay K. Harness, MD; Robert D. Siegel, MD, FACP; Diane B. Paul, AAS; Charles S. Cleeland, PhD; Deborah Schrag, MD, MPH; Jeff A. Sloan, PhD; Amy P. Abernethy, MD, PhD; Deborah W. Bruner, RN, PhD, FAAN; Lori M. Minasian, MD, FACP; Ethan Basch, MD, MSc; for the National Cancer Institute PRO-CTCAE Study Group

JAMA Oncol. 2015;1(8):1051-1059.



Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library (version 1)

Certified Translation

This is to certify that the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library (version 1) was translated from English to Italian using a universal translation methodology including representation from major Italian speaking regions by qualified translators employed by Italian National Cancer Institute, under the direction of the US National Cancer Institute.

This translation followed the translation methodology recommended by International Society of Pharmacoeconomic and Outcomes Research (ISPOR) a methodology established to ensure that resulting translations of patient-reported outcome measures reflect conceptual equivalence with the source document rendered in language that is culturally acceptable and relevant to the target population. This rigorous methodology requires two forward translations into the target language by native speakers, a reconciled version of the two forward translations into the target language by native speakers, a reconciled version of the two forward translations of the reconciled version by a native English speaker fluent in the target language, a back translation of the reconciled version by a native English speaker fluent in the target language, and an independent review by a native speaker transle as a physician or nurse in oncology.

After the translation phase was completed, the PRO-CITCAE tem Library (version 1) was linguistically validated by testing with patients to confirm suitability of the translations for Italian speaking patients. All translation owork was performed by members of the Italian translation team to the best of their abilities as native speakers of Italian (or English in the case of the back-translator), and as translators and researchers experienced in the field of health-related quality of life and patient-reported outcomes survey research under the direction of the undersigned.

This translation is, to the best of my knowledge, a valid and accurate translation of the corresponding original English language version of the PRO-CTCAE Item Library (version 1).

Name: Sandra A. Mitchell, PhD, CRNP Title: Research Scientist and Program Director; Outcomes Research Branch; US National Cancer Institute Signature: Date: June 5, 2017

NCI- PRO-CTCAE[™] ITEMS-ITALIAN

Item Library Version 1.0

Quando un individuo è in terapia per un tumore, talvolta può sviluppare diversi sintomi ed effetti collaterali. Per ciascuna domanda, fare un segno o una $\begin{pmatrix} X \\ X \end{pmatrix}$ nella casella che meglio corrisponde all'esperienza vissuta negli ultimi sette giorni...

 PRO-CTCAE[™] Symptom Term: Dry mouth 						
SENSAZIONE DI BOCCA SECCA						
Negli ultimi 7 giorni, quanto è stata GRAVE la SENSAZIONE DI BOCCA SECCA nel momento PEGGIORE?						
O Per nulla	O Un po'	O Abbastanza	O Molto	O Moltissimo		

PRO-CTCAE[™] Symptom Term: Difficulty swallowing					
DIFFICOLTÀ A DEGLUTIRE					
Negli ultimi 7 giorni, quanto è stata GRAVE la DIFFICOLTÀ A DEGLUTIRE nel momento PEGGIORE?					
O Per nulla	O Un po'	O Abbastanza	O Molto	O Moltissimo	

PRO-CTCAE[™] Symptom Term: Mouth/throat sores							
PIAGHE IN BOCCA O IN GOLA							
Negli ultimi 7 giorni, quanto sono state GRAVI le PIAGHE IN BOCCA O IN GOLA nel momento PEGGIORE?							
O Per nulla	O Un po'	O Abbastanza	O Molto	O Moltissimo			
Negli ultimi 7 giorni, in che misura le PIAGHE IN BOCCA O IN GOLA HANNO INTERFERITO con le Sue attività abituali o quotidiane?							
O Per nulla	O Un po'	O Abbastanza	O Molto	O Moltissimo			

	 PRO-CTCAE[™] Symptom Term: Cracking at the corners of the mouth (cheilosis/cheilitis) 								
	SCREPOLATURE AGLI ANGOLI DELLA BOCCA								
Negli ultimi 7 giorni, quanto sono state GRAVI le SCREPOLATURE AGLI ANGOLI DELLA BOCCA, nel momento PEGGIORE?									
	O Per nulla	O Un po'	O Abbastanza	O Molto	O Moltissimo				

The PRO-CTCAE^W items and information herein were developed by the Division of Cancer Control and Population Sciences in the NATIONAL CANCER INSTITUTE at the NATIONAL INSTITUTES OF HEALTH, in Bethesda, Maryland, U.S.A. Use of the PRO-CTCAE^W is subject to NCT's Terms of Use. https://healthcaredelivery .cancer.gov/pro-ctcae/proctcae_italian.pdf